All-in-all, no big deal. Maybe not for 'us in the know', but, the institutions are "blood-letting" bio-tech, cause their advisors are on the phone to "Patent Attornies" decifering (sp?) which companies are above the bar or not. (meanwhile, sell everything!) As an example of two companies scrambling to "get above the bar", read the Bristol-Myers & Athersys make deal article in NYT:http://www.nytimes.com/2001/01/08/business/08GENE.html(free registration) & read between the lines.Sort of a sector wide domino string falling, since the PTO guidelines are out.I expect more 'agreements/deals' in the near future from other'weak' companies in bio-tech. Maybe other companies waving their banner saying "whoopie for the high-jump" (although in bad taste) cause most institutions haven't a clue, and they are who moves markets..bg
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra